Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus FLUOCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus FLUOCINONIDE.
ALA-SCALP vs FLUOCINONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Fluocinonide is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a 5% solution to the scalp twice daily.
Topical: Apply a thin film to affected area 1-3 times daily. Limitation of use: Should not exceed 60 g per week in adults.
None Documented
None Documented
Clinical Note
moderateFluocinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin."
Clinical Note
moderateFluocinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin."
Clinical Note
moderateFluocinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin."
Clinical Note
moderateNot applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is approximately 1.3-2.4 hours in plasma. Clinically, due to high tissue binding and slow release from skin, the pharmacodynamic half-life for topical effect may extend to 12-24 hours.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily hepatic metabolism; inactive metabolites excreted renally and fecally. Renal elimination accounts for approximately 60-70% of total clearance, fecal elimination ~30-40%. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Fluocinonide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Trovafloxacin."